CT/GC EPT Distribution Program Eligibility

To be eligible to participate in the free Chlamydia/Gonorrhea (CT/GC) Expedited Partner Therapy (EPT) Distribution Program, each clinic site and local health jurisdiction (LHJ) is required to meet all of the following criteria.

Each clinic site and/or LHJ must:

  • Be located in California
  • Serve a population that is at risk for STIs (sexually transmitted infections)
  • Serve a population that is uninsured or underinsured. This may be demonstrated by meeting one or more of the following criteria:
    • Affiliation with a local health jurisdiction
    • Designation as a Federally Qualified Health Center (FQHC), FQHC Look-Alike, or Rural Health Clinic (RHC)
    • Member of a community clinic consortium
    • Participation in the 340B Drug Pricing Program
    • Receipt of Ryan White funding
    • Receipt of Title X funding
    • Site pre-approved by Essential Access Health

Additionally, each clinic site or LHJ must meet at least one of the following requirements for delivery of patient chlamydia and gonorrhea treatment:

  • Direct Onsite Dispensing - Provide direct onsite dispensing of chlamydia and gonorrhea medication to patients for their own treatment in the clinical setting. In this case, medication from the CT/GC EPT Distribution Program can be provided to the patient by clinic staff.
  • Onsite Pharmacy - Provide chlamydia and gonorrhea medication to patients for their own treatment through an onsite pharmacy. In this case, medication from the CT/GC EPT Distribution Program would be distributed by the pharmacist when filling the patients’ treatment.
  • Field-Delivered Treatment - Provide medication from the CT/GC EPT Distribution Program to patients and/or their sex partners through field-delivered treatment (FDT). This option is only available to LHJs.

Learn more about the patient treatment requirement on our FAQ page.

text of the organization's tagline

Essential Access Health is closed Dec 23-Jan 3. Happy holidays + looking forward to collaborating in 2025. Support Our Work